Did you know that Hepatitis C is the most common reason for liver transplants in the United States?
Hepatitis C is a viral infection that affects the liver. Hepatitis C is transmitted through the blood. The most common way people in the US become infected with the Hepatitis C virus is through sharing of needles or other equipment to inject drugs. Needle stick injuries in health care settings can also cause the spread of the virus. A new baby born to a mother who is Hepatitis C positive can also become infected. Less common ways that a person may contract Hepatitis C is by sharing personal items that have come in contact with an infected person’s blood, such as toothbrushes and razors, or having sexual contact with an infected individual.
Hepatitis C can be an acute or chronic infection. About 75% to 85% of people infected with Hepatitis C virus will develop a chronic infection. Chronic Hepatitis C can lead to liver damage, including cirrhosis or liver cancer. According to the CDC, 3.2 million people in the United States have chronic Hepatitis C infection. Chronic Hepatitis C can lead to serious health complications and even death.
In May 2011, two new medications were approved for the treatment of chronic Hepatitis C – Incivek (telaprevir) and Victrelis (boceprevir). Both medications are protease inhibitors. Protease inhibitors work by binding to the virus and preventing it from multiplying. These medications must be used in combination with peginterferon alfa and ribavirin. Peginterferon alfa and ribivirin have been the standard of care for people with Hepatitis C infection. Unfortunately, less than 50 percent of people who use this therapy regimen for 48 weeks respond. When one of the 2 new medications is added to peginterferon alfa and ribavirin, much better response rates are seen. According to the FDA, the response rates for therapy that included Incivek were 20% to 45% higher than standard care alone. Also instead of the 48 week regimen used previously, some patients may only have to be treated for 24 weeks to achieve a response.
However, Incivek and Victrelis are not for everyone. These medications can cause birth defects, anemia (low red blood cell count), as well as other adverse effects. Incivek and Victrelis can also interact with a number of medications. If you have Hepatitis C, and want to know if either of these medications would be appropriate for you, talk to your health care provider.
